Pet Pharm Biotech Co (ROCO:7762) EBIT: NT$25.1 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7762 Pet Pharm Biotech Co Ltd ROCO:7762
19 GF Score
Price NT$49.85
! 5 Warning Signs
View Full Analysis

What is Pet Pharm Biotech Co EBIT?

Pet Pharm Biotech Co ROCO:7762 +0.20% 19 EBIT is NT$25.1 Mil as of Dec. 2025. GuruFocus rates ROCO:7762 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review.

Pet Pharm Biotech Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was NT$16.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$25.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pet Pharm Biotech Co's annualized ROC % for the quarter that ended in Dec. 2025 was 3.37%. Pet Pharm Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 8.39%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pet Pharm Biotech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 1.00%.

Pet Pharm Biotech Co  (ROCO:7762) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pet Pharm Biotech Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=23.304 * ( 1 - 0% )/( (588.812 + 792.216)/ 2 )
=23.304/690.514
=3.37 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1104.561 - 29.192 - ( 571.689 - max(0, 143.169 - 629.726+571.689))
=588.812

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1347.053 - 35.979 - ( 518.858 - max(0, 56.249 - 600.552+518.858))
=792.216

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Pet Pharm Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=33.638/( ( (343.78 + max(23.125, 0)) + (395.061 + max(40.145, 0)) )/ 2 )
=33.638/( ( 366.905 + 435.206 )/ 2 )
=33.638/401.0555
=8.39 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(40.333 + 9.242 + 7.202) - (29.192 + 0 + 4.46)
=23.125

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(59.353 + 14.638 + 7.7030000000001) - (35.979 + 0 + 5.57)
=40.145

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pet Pharm Biotech Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=25.066/2507.887
=1.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pet Pharm Biotech Co EBIT Related Terms

Pet Pharm Biotech Co EBIT Historical Data

* Premium members only.

The historical data trend for Pet Pharm Biotech Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pet Pharm Biotech Co EBIT Chart

Pet Pharm Biotech Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBIT
-3.61 9.32 12.60 25.07

Pet Pharm Biotech Co Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial 4.38 3.46 9.13 8.25 16.82

ROCO:7762 vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pet Pharm Biotech Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pet Pharm Biotech Co's EV-to-EBIT falls into.


ROCO:7762
19GF Score
Pet Pharm Biotech Co Ltd ROCO:7762
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pet Pharm Biotech Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$25.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$25.1 Mil mean?
Pet Pharm Biotech Co (ROCO:7762) has a EBIT of NT$25.1 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pet Pharm Biotech Co.
Is Pet Pharm Biotech Co's EBIT too high?
Pet Pharm Biotech Co's current EBIT is NT$25.1 Mil. Overall, Pet Pharm Biotech Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's EBIT compare to LLY and JNJ?
Pet Pharm Biotech Co's EBIT of NT$25.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pet Pharm Biotech Co. Pet Pharm Biotech Co's current EBIT is NT$25.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current EBIT of NT$25.1 Mil. The current EBIT is NT$25.1 Mil. Pet Pharm Biotech Co's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current EBIT is NT$25.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pet Pharm Biotech Co Business Description

Address 143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
19GF Score

Get the complete analysis for ROCO:7762

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$49.85
Price